PL415351A1 - Sposób namnażania in vitro komórek T regulatorowych (Treg) - Google Patents

Sposób namnażania in vitro komórek T regulatorowych (Treg)

Info

Publication number
PL415351A1
PL415351A1 PL415351A PL41535115A PL415351A1 PL 415351 A1 PL415351 A1 PL 415351A1 PL 415351 A PL415351 A PL 415351A PL 41535115 A PL41535115 A PL 41535115A PL 415351 A1 PL415351 A1 PL 415351A1
Authority
PL
Poland
Prior art keywords
cells
tregs
regulatory
treg
vitro propagation
Prior art date
Application number
PL415351A
Other languages
English (en)
Other versions
PL236046B1 (pl
Inventor
Natalia Marek-Trzonkowska
Piotr Trzonkowski
Małgorzata Myśliwiec
Original Assignee
Gdański Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gdański Uniwersytet Medyczny filed Critical Gdański Uniwersytet Medyczny
Priority to PL415351A priority Critical patent/PL236046B1/pl
Priority to PT168340560T priority patent/PT3402877T/pt
Priority to RS20260241A priority patent/RS67800B1/sr
Priority to LTEPPCT/PL2016/000152T priority patent/LT3402877T/lt
Priority to EP16834056.0A priority patent/EP3402877B1/en
Priority to FIEP16834056.0T priority patent/FI3402877T3/fi
Priority to ES16834056T priority patent/ES3062934T3/es
Priority to US16/063,144 priority patent/US11072779B2/en
Priority to DK16834056.0T priority patent/DK3402877T3/da
Priority to PCT/PL2016/000152 priority patent/WO2017105265A1/en
Publication of PL415351A1 publication Critical patent/PL415351A1/pl
Publication of PL236046B1 publication Critical patent/PL236046B1/pl
Priority to US17/381,192 priority patent/US20210348126A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/48—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia jest nowy sposób namnażania in wtro komórek Treg CD4+CD25HighCD127-/LowFoxP3+, gdzie: proces namnażania komórek Treg odbywa się przez cały czas lub okresowo w temperaturze poniżej 37°C, optymalnie w temperaturze 33°C, wyizolowane komórki Treg namnaża się w pożywce SCGM lub X-vivo-20 suplementowanej ludzką surowicą lub płodową surowicą bydlęcą, do hodowli dodawane są mikrosfery magnetyczne opłaszczone przeciwciałami anty-CD3 i anty-CD28 w stosunku 1 : 1 (komórka: mikrosfera) oraz interleukina 2.
PL415351A 2015-12-17 2015-12-17 Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+ PL236046B1 (pl)

Priority Applications (11)

Application Number Priority Date Filing Date Title
PL415351A PL236046B1 (pl) 2015-12-17 2015-12-17 Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+
FIEP16834056.0T FI3402877T3 (fi) 2015-12-17 2016-12-19 Menetelmä säätelevien T-solujen lisäämiseksi ex vivo
RS20260241A RS67800B1 (sr) 2015-12-17 2016-12-19 Postupak za ex vivo ekspanziju regulatornih t ćelija
LTEPPCT/PL2016/000152T LT3402877T (lt) 2015-12-17 2016-12-19 Reguliacinių t ląstelių ex vivo dauginimo būdas
EP16834056.0A EP3402877B1 (en) 2015-12-17 2016-12-19 Method for ex vivo expansion of regulatory t cells
PT168340560T PT3402877T (pt) 2015-12-17 2016-12-19 Método para expansão ex vivo de células t reguladoras
ES16834056T ES3062934T3 (en) 2015-12-17 2016-12-19 Method for ex vivo expansion of regulatory t cells
US16/063,144 US11072779B2 (en) 2015-12-17 2016-12-19 Method for ex vivo expansion of regulatory T cells
DK16834056.0T DK3402877T3 (da) 2015-12-17 2016-12-19 Metode til ex vivo-ekspansion af regulerende t-celler
PCT/PL2016/000152 WO2017105265A1 (en) 2015-12-17 2016-12-19 Method for ex vivo expansion of regulatory t cells
US17/381,192 US20210348126A1 (en) 2015-12-17 2021-07-21 Method for ex vivo expansion of regulatory t cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL415351A PL236046B1 (pl) 2015-12-17 2015-12-17 Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+

Publications (2)

Publication Number Publication Date
PL415351A1 true PL415351A1 (pl) 2017-06-19
PL236046B1 PL236046B1 (pl) 2020-11-30

Family

ID=57960799

Family Applications (1)

Application Number Title Priority Date Filing Date
PL415351A PL236046B1 (pl) 2015-12-17 2015-12-17 Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+

Country Status (10)

Country Link
US (1) US11072779B2 (pl)
EP (1) EP3402877B1 (pl)
DK (1) DK3402877T3 (pl)
ES (1) ES3062934T3 (pl)
FI (1) FI3402877T3 (pl)
LT (1) LT3402877T (pl)
PL (1) PL236046B1 (pl)
PT (1) PT3402877T (pl)
RS (1) RS67800B1 (pl)
WO (1) WO2017105265A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018106885A1 (en) 2016-12-07 2018-06-14 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
PL241050B1 (pl) * 2019-12-12 2022-07-25 Gdanski Univ Medyczny Zastosowanie limfocytów T regulatorowych jako leku w leczeniu stwardnienia rozsianego
CN113564117B (zh) * 2021-08-23 2023-12-26 山东省齐鲁干细胞工程有限公司 一种冻存脐带血来源调节性t细胞体外扩增优化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005206746B2 (en) * 2004-01-08 2008-08-28 Regents Of The University Of California Regulatory t cells suppress autoimmunity
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
WO2010135255A1 (en) 2009-05-18 2010-11-25 Therakos, Inc. Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases
WO2013050596A1 (en) 2011-10-06 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of maintaining foxp3 expression in expanded t regulatory cell
EP2804625A4 (en) * 2012-01-17 2015-10-28 Univ Northeastern METHOD AND COMPOSITIONS FOR THE EXPANSION OF IMMUNOSUPPRESSIVE REGULATORY T CELLS IN VITRO AND USES THEREOF
PL218400B1 (pl) 2012-06-06 2014-11-28 Gdański Univ Medyczny Szczepionka do leczenia cukrzycy typu 1 u dzieci, zastosowanie sortera komórek oraz sposób namnażania komórek Treg in vitro do wytwarzania szczepionki do leczenia cukrzycy typu 1

Also Published As

Publication number Publication date
RS67800B1 (sr) 2026-03-31
PL236046B1 (pl) 2020-11-30
US20180362928A1 (en) 2018-12-20
PT3402877T (pt) 2026-03-03
FI3402877T3 (fi) 2026-02-11
DK3402877T3 (da) 2026-02-23
LT3402877T (lt) 2026-03-10
ES3062934T3 (en) 2026-04-14
EP3402877B1 (en) 2025-11-26
US11072779B2 (en) 2021-07-27
EP3402877A1 (en) 2018-11-21
WO2017105265A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
Putnam et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation
Bahri et al. Ectonucleotidase CD38 demarcates regulatory, memory-like CD8+ T cells with IFN-γ-mediated suppressor activities
Dwyer et al. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype
BR112020016176A2 (pt) Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
Taflin et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions
Akimova et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs
Chellappa et al. Regulatory T cells that co-express RORγt and FOXP3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer
EA202091407A1 (ru) Состав бессывороточной среды для культивирования клеток и способы его применения
Kobyzeva et al. CD56dimCD57− NKG2C+ NK cells retaining proliferative potential are possible precursors of CD57+ NKG2C+ memory-like NK cells
MX2019010583A (es) Anticuerpos contra ligando 1 de muerte programada.
MY180750A (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
MA39867A (fr) Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
NZ725201A (en) Improved methods for manufacturing adoptive cell therapies
Sato et al. Impact of culture medium on the expansion of T cells for immunotherapy
Moreira-Teixeira et al. Rapamycin combined with TGF-β converts human invariant NKT cells into suppressive Foxp3+ regulatory cells
EP4458419A3 (en) Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
Lu et al. iTreg induced from CD39+ naive T cells demonstrate enhanced proliferate and suppressive ability
WO2021101273A3 (ko) 조절 t 세포 배양용 조성물 및 이의 용도
PL415351A1 (pl) Sposób namnażania in vitro komórek T regulatorowych (Treg)
Peragine et al. Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients
Grinnemo et al. Immunomodulatory effects of interferon-γ on human fetal cardiac mesenchymal stromal cells
DiSpirito et al. Histone acetylation at the single-cell level: a marker of memory CD8+ T cell differentiation and functionality
Gołąb et al. Impact of culture medium on CD4+ CD25highCD127lo/neg Treg expansion for the purpose of clinical application
BR112021021349A2 (pt) Métodos de fabricação de células car t alogênicas
Lipscomb et al. DC expressing transgene Foxp3 are regulatory APC